Oxford Asset Management’s ResMed RMD Stock Holding History

Oxford Asset Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-790	Closed	-$204K	–	693
2025 Q2	$204K	Buy	+790	New	+$188K	0.07%	424
2024 Q4	–	Sell	-1,204	Closed	-$294K	–	577
2024 Q3	$294K	Buy	+1,204	New	+$269K	0.24%	168
2019 Q1	–	Sell	-10,196	Closed	-$1.16M	–	1929
2018 Q4	$1.16M	Buy	10,196 +3,394	+50%	+$364K	0.03%	786
2018 Q3	$779K	Sell	6,802 -9,036	-57%	-$990K	0.02%	1120
2018 Q2	$1.65M	Buy	+15,838	New	+$1.6M	0.03%	774

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Oxford Asset Management's RMD Position: Q3 2025 in Review

Oxford Asset Management sold out of ResMed (RMD) in Q3 2025, closing a stake of 790 shares — an estimated $204K sold.

Oxford Asset Management first reported a position in RMD in Q2 2018 and held it in 5 quarters. The position peaked at $1.65M in Q2 2018. 950 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

Oxford Asset Management reported no remaining ResMed position as of Q3 2025 after selling out during the quarter.
Oxford Asset Management sold 790 ResMed shares in Q3 2025, an estimated $204K.
Oxford Asset Management first reported a position in ResMed in Q2 2018 and held it in 5 quarters.
Oxford Asset Management's ResMed position peaked at $1.65M in Q2 2018.
950 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Oxford Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.